Repetitive Transcranial Magnetic Stimulation in Obsessive Compulsive Disorder

Last updated: May 7, 2020
Sponsor: University Hospital, Grenoble
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kleptomania

Obsessive-compulsive Disorder

Anxiety Disorders

Treatment

N/A

Clinical Study ID

NCT02884674
38RC14.156
2014-A00668-39
  • Ages > 18
  • All Genders

Study Summary

Evaluate the therapeutic effect of a functional Magnetic Resonance Imaging (fMRI)-guided and robotized neuronavigated theta burst Transcranial Magnetic Stimulation (TMS) targeting right inferior frontal region in resistant obsessive compulsive disorder (OCD) in a double-blind, randomized, placebo-controlled, monocentric study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Volunteer subjects with Obsessive Compulsive Disorders (OCD) according to theDiagnostic and Statistical Manual of Mental Disorders (DSM IV-TR) criteria andvalidated by an experimented clinician following instruments like SCID (StructuredClinical Interview for DSM IV) or MINI (Mini-International Neuropsychiatric Interview)

  • with or without associated tics ("Gilles de la Tourette" Syndrome)

  • Age > 18 years old

  • Y-BOCS score > 20 and CGI (Clinical Global Impression Scale) score ≥ 4

  • Resistant patients to standard treatments - where treatment resistance is defined bypartial but insufficient response (Global Assessment of Functioning score GAF score < 60 and/or reduction of Yale Brown Obsessions and Compulsion Scale score < 35%) or lackof response to previous well conducted treatment including:

  • pharmacotherapy : optimal tolerated dose and adequate duration (> 12 weeks) of atleast 2 Serotonin Reuptake Inhibitors (selective serotonin reuptake inhibitors,clomipramine), and one augmentation strategy (adjunction of an antipsychotic -such as risperidone or olanzapine or aripiprazole - or lithium or buspirone) ;

  • psychotherapy (at least 6 months of cognitive and behavioral therapy)

Exclusion

Exclusion Criteria:

  • other primary diagnosis than OCD (comorbid tics and depression are tolerated)

  • comorbid diagnosis of schizophrenia/ psychotic disorder, bipolar disorder, substanceabuse or dependance

  • medical condition involving cognitive decline and affecting brain structures such asParkinson disease, dementia, multiple sclerosis, HIV (human immunodeficiency virus)infection, lupus etc.

  • Magnetic Resonance Imaging exclusion criteria (ferromagnetic implants etc)

  • common TMS exclusion criteria (neurological condition with an increased risk ofseizure, cardiac pacemakers, implanted medication pumps, intracardiac lines, or acute,unstable cardiac disease, intracranial implants (e.g. cochlear implants, electrodes,aneurysm clips, stimulators... ) or any other metal object within or near the head,excluding the mouth, that cannot be safely removed will be excluded

  • Current use of any investigational drug

  • pregnancy / breast feeding patients

  • visual or auditive important deficit

Study Design

Total Participants: 56
Study Start date:
May 01, 2015
Estimated Completion Date:
May 31, 2021

Study Description

This study evaluates the therapeutic effect of a fMRI-guided and robotized neuronavigated theta burst Transcranial Magnetic Stimulation (TMS) targeting right inferior frontal region in resistant obsessive compulsive disorder (OCD) in a double-blind, randomized, placebo-controlled, monocentric study. The study will also assess the interest of some clinical, neuropsychological, neuroimaging, electrophysiological variables in response prediction, besides physiopathological information.

There is an increasing interest in developping treatments for resistant OCD, which are not responding to the conventional treatment, represented by pharmacotherapy associated to cognitive behavioral therapy. Repetitive TMS represents a promising non invasive brain stimulation approach, but efficacy, best available brain target, optimal responder profile and stimulation parameters need to be further documented.

In this study, the included patients will be randomly assigned to an active (theta burst TMS) or sham-placebo treatment group. TMS will be added to their stable pharmacotherapy. The brain target, the right inferior frontal region, involved in the inhibition control brain network, will be defined in a personalized manner via a fMRI paradigm for each patient. TMS will be delivered daily for 2 successive weeks. Measures of different clinical, neuropsychological , electrophysiological (cortical excitability) variables will be performed at baseline, as well as at the end of the TMS course, and 1 week after. Other assessments are planned at 3 and 6 months, in order to highlight the evolution of the potential benefit.

Connect with a study center

  • CHU de Grenoble - Pavillon Dominique Villars

    Grenoble, Rhone Alpes 38000
    France

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.